

# Kevin O Saunders

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1148876/publications.pdf>

Version: 2024-02-01

75  
papers

5,213  
citations

117453

34  
h-index

110170

64  
g-index

94  
all docs

94  
docs citations

94  
times ranked

6919  
citing authors

#	ARTICLE	IF	CITATIONS
1	Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. <i>Journal of Experimental Medicine</i> , 2018, 215, 1571-1588.	4.2	366
2	Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity. <i>Science</i> , 2021, 373, .	6.0	318
3	A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice. <i>Immunity</i> , 2020, 53, 724-732.e7.	6.6	267
4	InÂvitro and inÂvivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. <i>Cell</i> , 2021, 184, 4203-4219.e32.	13.5	228
5	Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection. <i>Cell</i> , 2015, 161, 470-485.	13.5	226
6	Staged induction of HIV-1 glycanâ€“dependent broadly neutralizing antibodies. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	212
7	Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life. <i>Frontiers in Immunology</i> , 2019, 10, 1296.	2.2	211
8	Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. <i>Nature</i> , 2021, 594, 553-559.	13.7	199
9	Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice. <i>Science</i> , 2021, 373, 991-998.	6.0	144
10	Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge. <i>Nature Communications</i> , 2017, 8, 15711.	5.8	137
11	Structural diversity of the SARS-CoV-2 Omicron spike. <i>Molecular Cell</i> , 2022, 82, 2050-2068.e6.	4.5	125
12	Potent and broad HIV-neutralizing antibodies in memory B cells and plasma. <i>Science Immunology</i> , 2017, 2, .	5.6	119
13	Targeted selection of HIV-specific antibody mutations by engineering B cell maturation. <i>Science</i> , 2019, 366, .	6.0	118
14	Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection. <i>Journal of Virology</i> , 2015, 89, 8334-8345.	1.5	100
15	Functional Relevance of Improbable Antibody Mutations for HIV Broadly Neutralizing Antibody Development. <i>Cell Host and Microbe</i> , 2018, 23, 759-765.e6.	5.1	98
16	Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models. <i>Cell Reports</i> , 2017, 21, 3681-3690.	2.9	97
17	A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice. <i>Science Translational Medicine</i> , 2022, 14, eabj7125.	5.8	93
18	Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection. <i>Journal of Virology</i> , 2015, 89, 5895-5903.	1.5	92

#	ARTICLE	IF	CITATIONS
19	Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19. <i>Cell</i> , 2020, 181, 1458-1463.	13.5	92
20	SARS-CoV-2 Neutralizing Antibodies for COVID-19 Prevention and Treatment. <i>Annual Review of Medicine</i> , 2022, 73, 1-16.	5.0	91
21	Antibodies VRC01 and 10E8 Neutralize HIV-1 with High Breadth and Potency Even with Ig-Framework Regions Substantially Reverted to Germline. <i>Journal of Immunology</i> , 2014, 192, 1100-1106.	0.4	86
22	Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	81
23	Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations. <i>Nature Communications</i> , 2017, 8, 1732.	5.8	76
24	Cryo-EM structures of SARS-CoV-2 Omicron BA.2 spike. <i>Cell Reports</i> , 2022, 39, 111009.	2.9	74
25	Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates. <i>Cell Reports</i> , 2017, 18, 2175-2188.	2.9	69
26	Cold sensitivity of the SARS-CoV-2 spike ectodomain. <i>Nature Structural and Molecular Biology</i> , 2021, 28, 128-131.	3.6	65
27	Mapping the SARS-CoV-2 spike glycoprotein-derived peptidome presented by HLA class II on dendritic cells. <i>Cell Reports</i> , 2021, 35, 109179.	2.9	63
28	Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier. <i>Immunity</i> , 2018, 49, 1162-1174.e8.	6.6	61
29	Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies. <i>Cell</i> , 2021, 184, 2955-2972.e25.	13.5	57
30	Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies. <i>PLoS Pathogens</i> , 2019, 15, e1008026.	2.1	56
31	Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth. <i>Science</i> , 2021, 371, .	6.0	49
32	Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	49
33	Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates. <i>Npj Vaccines</i> , 2021, 6, 50.	2.9	46
34	Co-immunization of DNA and Protein in the Same Anatomical Sites Induces Superior Protective Immune Responses against SHIV Challenge. <i>Cell Reports</i> , 2020, 31, 107624.	2.9	43
35	Disruption of the HIV-1 Envelope allosteric network blocks CD4-induced rearrangements. <i>Nature Communications</i> , 2020, 11, 520.	5.8	42
36	Consistent elicitation of cross-clade HIV-neutralizing responses achieved in guinea pigs after fusion peptide priming by repetitive envelope trimer boosting. <i>PLoS ONE</i> , 2019, 14, e0215163.	1.1	41

#	ARTICLE	IF	CITATIONS
37	Development of mRNA manufacturing for vaccines and therapeutics: mRNA platform requirements and development of a scalable production process to support early phase clinical trials. <i>Translational Research</i> , 2022, 242, 38-55.	2.2	41
38	Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost. <i>Journal of Virology</i> , 2015, 89, 6462-6480.	1.5	40
39	Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial. <i>PLoS Pathogens</i> , 2017, 13, e1006182.	2.1	38
40	HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies. <i>PLoS Pathogens</i> , 2018, 14, e1007431.	2.1	36
41	Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations. <i>Nature Communications</i> , 2019, 10, 2898.	5.8	35
42	Selection of immunoglobulin elbow region mutations impacts interdomain conformational flexibility in HIV-1 broadly neutralizing antibodies. <i>Nature Communications</i> , 2019, 10, 654.	5.8	34
43	Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial. <i>Nature Medicine</i> , 2022, 28, 1022-1030.	15.2	34
44	Star nanoparticles delivering HIV-1 peptide minimal immunogens elicit near-native envelope antibody responses in nonhuman primates. <i>PLoS Biology</i> , 2019, 17, e3000328.	2.6	33
45	Secretion of MIP-1 $\beta$ and MIP-1 $\alpha$ by CD8 <sup>+</sup> T-lymphocytes correlates with HIV-1 inhibition independent of coreceptor usage. <i>Cellular Immunology</i> , 2011, 266, 154-164.	1.4	28
46	Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines. <i>PLoS Medicine</i> , 2020, 17, e1003038.	3.9	27
47	Immune checkpoint modulation enhances HIV-1 antibody induction. <i>Nature Communications</i> , 2020, 11, 948.	5.8	27
48	Maternal Broadly Neutralizing Antibodies Can Select for Neutralization-Resistant, Infant-Transmitted/Founder HIV Variants. <i>MBio</i> , 2020, 11, .	1.8	25
49	mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice. <i>Cell Reports</i> , 2022, 38, 110514.	2.9	23
50	Glycoengineering HIV-1 Env creates "supercharged" and "hybrid" glycans to increase neutralizing antibody potency, breadth and saturation. <i>PLoS Pathogens</i> , 2018, 14, e1007024.	2.1	22
51	Antibody responses to the HIV-1 envelope high mannose patch. <i>Advances in Immunology</i> , 2019, 143, 11-73.	1.1	22
52	Neonatal Rhesus Macaques Have Distinct Immune Cell Transcriptional Profiles following HIV Envelope Immunization. <i>Cell Reports</i> , 2020, 30, 1553-1569.e6.	2.9	21
53	HIV DNA-Adenovirus Multiclade Envelope Vaccine Induces gp41 Antibody Immunodominance in Rhesus Macaques. <i>Journal of Virology</i> , 2017, 91, .	1.5	20
54	Strategies for induction of HIV-1 envelope-reactive broadly neutralizing antibodies. <i>Journal of the International AIDS Society</i> , 2021, 24, e25831.	1.2	19

#	ARTICLE	IF	CITATIONS
55	HIV vaccine delayed boosting increases Env variable region 2â€™specific antibody effector functions. JCI Insight, 2020, 5, .	2.3	18
56	Epigenetic regulation of CD8+ T-lymphocyte mediated suppression of HIV-1 replication. Virology, 2010, 405, 234-242.	1.1	15
57	Mouse and human antibodies bind HLA-E-leader peptide complexes and enhance NK cell cytotoxicity. Communications Biology, 2022, 5, 271.	2.0	14
58	Therapeutic vaccination with IDLV-SIV-Gag results in durable viremia control in chronically SHIV-infected macaques. Npj Vaccines, 2020, 5, 36.	2.9	12
59	Immunogenicity, safety, and efficacy of sequential immunizations with an SIV-based IDLV expressing CH505 Envs. Npj Vaccines, 2020, 5, 107.	2.9	11
60	Functional Homology for Antibody-Dependent Phagocytosis Across Humans and Rhesus Macaques. Frontiers in Immunology, 2021, 12, 678511.	2.2	11
61	Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates. Journal of Virology, 2018, 92, .	1.5	10
62	Rapid selection of HIV envelopes that bind to neutralizing antibody B cell lineage members with functional improbable mutations. Cell Reports, 2021, 36, 109561.	2.9	9
63	HIV envelope antigen valency on peptide nanofibers modulates antibody magnitude and binding breadth. Scientific Reports, 2021, 11, 14494.	1.6	6
64	B cells expressing IgM B cell receptors of HIV-1 neutralizing antibodies discriminate antigen affinities by sensing binding association rates. Cell Reports, 2022, 39, 111021.	2.9	6
65	Cooperation between somatic mutation and germline-encoded residues enables antibody recognition of HIV-1 envelope glycans. PLoS Pathogens, 2019, 15, e1008165.	2.1	5
66	Antigenicity and Immunogenicity of HIV-1 Envelope Trimers Complexed to a Small-Molecule Viral Entry Inhibitor. Journal of Virology, 2020, 94, .	1.5	5
67	Frequent Development of Broadly Neutralizing Antibodies in Early Life in a Large Cohort of Children With Human Immunodeficiency Virus. Journal of Infectious Diseases, 2022, 225, 1731-1740.	1.9	5
68	Parallel Induction of CH505 B Cell Ontogeny-Guided Neutralizing Antibodies and tHIVconsvX Conserved Mosaic-Specific T Cells against HIV-1. Molecular Therapy - Methods and Clinical Development, 2019, 14, 148-160.	1.8	4
69	Exploiting Pre-Existing CD4+ T Cell Help from Bacille Calmetteâ€™GuÃ©rin Vaccination to Improve Antiviral Antibody Responses. Journal of Immunology, 2020, 205, 425-437.	0.4	3
70	Polyclonal Broadly Neutralizing Antibody Activity Characterized by CD4 Binding Site and V3-Glycan Antibodies in a Subset of HIV-1 Virus Controllers. Frontiers in Immunology, 2021, 12, 670561.	2.2	3
71	Structural and genetic convergence of HIV-1 neutralizing antibodies in vaccinated non-human primates. PLoS Pathogens, 2021, 17, e1009624.	2.1	2
72	â€™â€™â€™Rapid Selection of HIV Envelopes that Bind to Neutralizing Antibody B Cell Lineage Members with Functional Improbable Mutations. SSRN Electronic Journal, 0, , .	0.4	1

#	ARTICLE	IF	CITATIONS
73	Structure and Fc-Effector Function of Rhesusized Variants of Human Anti-HIV-1 IgG1s. <i>Frontiers in Immunology</i> , 2021, 12, 787603.	2.2	1
74	-Deficient Mice Exhibit Cytokine-Related Transcriptomic Signatures. <i>ImmunoHorizons</i> , 2020, 4, 713-728.	0.8	0
75	RAB11FIP5-Deficient Mice Exhibit Cytokine-Related Transcriptomic Signatures. <i>ImmunoHorizons</i> , 2020, 4, 713-728.	0.8	0